Literature DB >> 30348712

Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma.

Nayra S Amaral1, Vivian Resende1, José Sebastião Dos Santos2, Luiz Felipe Lima1, Debora C Moraes1, Eitan Friedman3, Luiz DE Marco4, Luciana Bastos-Rodrigues5.   

Abstract

BACKGROUND/AIM: Ethnicity has an effect on survival in patients with pancreatic adenocarcinoma (PDAC), which may be reflected in the rate of somatic driver mutations. The Brazilian population represents au extensive interethnic admixture and little is known about the spectrum and rates of somatic driver mutations in Brazilian PDAC cases.
MATERIALS AND METHODS: Direct sequencing of six genes in 23 PDAC cases was performed and the ancestry of patients was determined using a validated panel of ancestry-informative insertion/deletion DNA polymorphisms.
RESULTS: KRAS proto-oncogene (KRAS) was the most commonly mutated gene (60%). A novel putatively pathogenic mutation in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (c.2948T>A; p.M983K) was identified. Mutations in epidermal growth factor receptor (EGFR) (4%), PIK3CA (4%), cyclin-dependent kinase inhibitor 2A (CDKN2A) (4%) and TP53 (8%) were noted, in rates that are less frequent than those reported for other populations. Mutations of B-Raf proto-oncogene, serine/threonine kinase (BRAF) were not present. All individuals with high African ancestral component (allelic frequency, >0.45) exhibited KRAS mutations.
CONCLUSION: Our results highlight the importance of the effect of ethnicity on somatic mutations in Brazilian patients with PDAC. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BRAF; CDKN2A; EGFR; KRAS; PIK3CA; Pancreatic cancer; TP53; ethnicity

Mesh:

Substances:

Year:  2018        PMID: 30348712      PMCID: PMC6365728          DOI: 10.21873/invivo.11410

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  30 in total

1.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

2.  The genetic structure of human populations studied through short insertion-deletion polymorphisms.

Authors:  Luciana Bastos-Rodrigues; Juliana R Pimenta; Sergio D J Pena
Journal:  Ann Hum Genet       Date:  2006-09       Impact factor: 1.670

Review 3.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 4.  Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.

Authors:  Puneet Singh; Radhika Srinivasan; Jai Dev Wig
Journal:  Pancreas       Date:  2011-07       Impact factor: 3.327

5.  Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis.

Authors:  Vinamrata Singal; Ashwani K Singal; Yong-Fang Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-15       Impact factor: 4.553

6.  Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

Authors:  Seung Tae Kim; Do Hyoung Lim; Kee-Taek Jang; Taekyu Lim; Jeeyun Lee; Yoon-La Choi; Hye-Lim Jang; Jun Ho Yi; Kyung Kee Baek; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.261

7.  Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic.

Authors:  A Naccarati; B Pardini; V Polakova; Z Smerhovsky; L Vodickova; P Soucek; D Vrana; I Holcatova; M Ryska; P Vodicka
Journal:  Carcinogenesis       Date:  2010-01-28       Impact factor: 4.944

8.  Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.

Authors:  Heike Immervoll; Dag Hoem; Kalaiarasy Kugarajh; Solrun J Steine; Anders Molven
Journal:  Virchows Arch       Date:  2006-04-06       Impact factor: 4.064

9.  A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.

Authors:  Diana Mandelker; Sandra B Gabelli; Oleg Schmidt-Kittler; Jiuxiang Zhu; Ian Cheong; Chuan-Hsiang Huang; Kenneth W Kinzler; Bert Vogelstein; L Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

10.  PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Authors:  Filip Janku; J Jack Lee; Apostolia M Tsimberidou; David S Hong; Aung Naing; Gerald S Falchook; Siqing Fu; Rajyalakshmi Luthra; Ignacio Garrido-Laguna; Razelle Kurzrock
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

View more
  1 in total

1.  Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG).

Authors:  George Zarkavelis; Vassiliki Kotoula; Georgia-Angeliki Kolliou; Kyriaki Papadopoulou; Ioannis Tikas; Vasilios Karavasilis; Epaminontas Samantas; Christos Dervenis; Ioannis Efstratiou; Irene Nicolaou; Dimitra Apessou; Georgia Kafiri; Triantafyllia Koletsa; Iliada Bompolaki; Grigorios Rallis; Anna Batistatou; George Glantzounis; Dimitrios Pectasides; George Fountzilas; George Pentheroudakis
Journal:  ESMO Open       Date:  2019-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.